- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00367237
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- The subject must meet ALL of the criteria listed below for entry into the study:
- Subject must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subject aged 18 years or more, of either sex and any race
Diagnosis of Psoriatic Arthritis with peripheral polyarticular involvement. Patients will have at least one of the following:
- Distal Interphalangeal Joints (DIP) involvement
- polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
- arthritis mutilans
- asymmetric peripheral arthritis
- Negative rheumatoid factor
- The disease should have been diagnosed at least 3 months prior to screening.
Active disease at the time of screening and prior to receiving the baseline study medication(s) as defined by:
- 5 or more swollen joints and
- 5 or more tender joints
and one out of the following three categories:
- Erythrocyte Sedimentation Rate (ESR) >= 28 mm/h
- C-reactive protein (CRP) >= 15 mg/l
- Morning stiffness >= 45 min
- Subjects must confirm that they are practicing adequate contraception: Female subjects of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active during the study) must agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male and female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g., hysterectomy or tubal ligation).
- Female subjects of childbearing potential must have a negative pregnancy test at Screening.
- Subjects must be eligible for anti-tumor necrosis factor (TNF) treatment according to applicable local guidelines. For all patients chest X-ray and skin test results must be available at baseline.
- If using Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids other than i.v., i.m. or i.a., the patient must be on a stable dose for four weeks prior screening (maximum dose up to 10mg/day of prednisone or its oral equivalent).
The screening laboratory tests must beet the following criteria:
- Hemoglobin >= 10 g/dl providing the low hemoglobin level is not due to other diseases than anemia of chronic inflammation.
- white blood cell (WBC) >= 3500 / μl
- Neutrophils >= 1500 / μl
- Platelets >= 100 000/ μl
- Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase <= 1.5 x upper limit of normal
- Total bilirubin <= 1 x upper limit of normal
- Serum creatinine <= 1.5 mg/dl
- Patient must be able to adhere to the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures.
Exclusion Criteria:
- The subject will be excluded from entry into the study if ANY of the criteria listed below are met:
- Subject is a female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
- Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis.
- Previous treatment with Infliximab.
- Subjects who have previously received MTX or have not discontinued their other DMARD therapy (i.e., sulfasalazine, hydroxychloroquine, leflunomide).
- Patients with fibromyalgia syndrome.
- Use of cyclosporine or tacrolimus within 4 weeks prior to screening. Use of IM, IV, or IA corticosteroids within 4 weeks prior to screening.
- Treatment with any investigational drug within 3 months prior to screening.
- Previous treatment with a monoclonal antibody or a fusion protein.
- A history of known allergy to murine proteins.
- History of infected joint prosthesis within the previous 5 years.
- Chronic infections.
- History of active tuberculosis requiring treatment within previous 3 years or history of opportunistic infections within 2 months, uncontrolled active infection or documented HIV infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis without documented adequate therapy, if they will not be treated according to local tuberculosis (TB) guidelines.
- Subject has any clinically significant deviation from normal in the physical examination, chest X-ray, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety.
- Current signs or symptoms of other severe uncontrolled diseases, which in the investigators opinion would put the patient at an unacceptable risk.
- History of lymphoproliferative disease, any current malignancies or history of malignancy within 5 years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin.
- Subject is part of the staff or a family member of the staff personnel directly involved with this study.
- History of drug abuse.
- Subjects who are participating in any other clinical study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Infliximab + methotrexate (IFX + MTX)
Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
|
Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks.
Methotrexate dose can be increased to 20 mg/week at week 6.
Otros nombres:
|
Comparador activo: Methotrexate (MTX)
Oral methotrexate (MTX) 15 mg/week
|
Oral methotrexate 15 mg/week for 15 weeks.
Dose can be increased to 20 mg/week at Week 6.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16
Periodo de tiempo: between baseline and week 16
|
>=20% improvement in swollen and tender joint count AND >=20% improvement in 3 of the following: visual analog scale (VAS) assessment of pain; subject VAS global assessment of disease activity; evaluator VAS global assessment of disease activity; Health Assessment Questionnaire (HAQ) disability index; C-Reactive Protein (CRP) level.
|
between baseline and week 16
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Proportion of Subjects Achieving ACR50, ACR70, and PASI75 if Applicable
Periodo de tiempo: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Change in Disease Activity Score, Each of the ACR20 Domains, Dactylitis, Enthesitis, Fatigue and Duration of Morning Stiffness, Erythrocyte Sedimentation Rate, and Disability Index of the Health Assessment Questionnaire (HAQ)
Periodo de tiempo: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Adverse Events
Periodo de tiempo: between baseline and week 16
|
This is not a prespecified key secondary outcome; therefore, results will not be disclosed.
|
between baseline and week 16
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades de la piel
- Enfermedades Articulares
- Enfermedades musculoesqueléticas
- Enfermedades De La Piel Papuloescamosa
- Enfermedades de la columna
- Enfermedades óseas
- Espondiloartropatías
- Espondiloartritis
- Espondilitis
- Soriasis
- Artritis
- Artritis, Psoriásica
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes antirreumáticos
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes Gastrointestinales
- Agentes dermatológicos
- Agentes de control reproductivo
- Agentes abortivos, no esteroideos
- Agentes abortivos
- Antagonistas del ácido fólico
- Metotrexato
- Infliximab
Otros números de identificación del estudio
- P04422
- EUDRACT #: 2005-002189-12
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infliximab + methotrexate (IFX + MTX)
-
Children's Hospital of Fudan UniversityReclutamientoEnfermedad de Crohn | Inmunosupresión | Niños, Solo | InfliximabPorcelana
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...TerminadoEnfermedad de CrohnFrancia
-
Centocor Ortho Biotech Services, L.L.C.Schering-PloughTerminadoEnfermedad de CrohnEstados Unidos, Francia, Reino Unido, Alemania, España, Bélgica, Israel, Grecia, Canadá, Países Bajos, Austria, Noruega, Dinamarca, Suecia, Portugal
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityReclutamientoColitis ulcerosa de moderada a gravePorcelana
-
Chinese University of Hong KongTerminadoEspondiloartritis anquilosante
-
Children's Memorial Health Institute, PolandDesconocidoEnfermedad de CrohnPolonia
-
Rehab WeridaTerminadoEnfermedades inflamatorias del intestinoEgipto
-
Merck Sharp & Dohme LLCTerminado
-
Helsinki University Central HospitalFoundation for Paediatric Research, Finland; Päivikki and Sakari Sohlberg Foundation... y otros colaboradoresTerminadoArtritis reumatoide juvenil idiopáticaFinlandia